一文总结:Ⅲ期NSCLC免疫治疗的发展现状与未来探索
干货满满!
参考文献:
[1]Cortiula F,et al.Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Ann Oncol. 2022 Sep;33(9):893-908.
[2]Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage Ⅲ Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311.
[3]Girard N,Smit H.J.M,Sibille A.et al.1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.Ann Oncol. 2021; 32: S939-S940.
[4]Zhou Q, Chen M, Jiang O, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2022 Feb;23(2):209-219.
[5]Durm G.A,Mamdani H,Althouse S.K,et al.Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.J Clin Oncol. 2022; 40 (8509-8509).De Ruysscher D.Herbst R.S.
[6]Majem M,Barlesi F,et al.COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non–small-cell lung cancer.J Clin Oncol. 2022; (In press).
[7]Peters S,Felip E,Dafni U.et al.Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—the ETOP NICOLAS trial.Lung Cancer. 2019; 133: 83-87.
[8]Peters S,Felip E,Dafni U,et al.Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: results from the European Thoracic oncology platform NICOLAS phase II Trial (European Thoracic Oncology Platform 6-14).J Thorac Oncol. 2021; 16: 278-288.
[9]Lin S.H,Lin Y,Yao L,et al.Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC.J Thorac Oncol. 2020; 15: 248-257.
[10]Ross H.J,Kozono D.E,Urbanic J.J,et al.AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).J Clin Oncol. 2021; 39 (8513-8513).
[11]Reck M,Lee K.H,Frost N.et al.Two-year update from KEYNOTE-799: pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.J Clin Oncol. 2022; 40 (8508-8508).
陈利娟 医学博士
河南省肿瘤医院肿瘤内科 副主任医师 郑州大学硕士研究生导师
英国玛丽女王伦敦大学Barts 癌症中心公派访问学者
河南省肿瘤诊断学重点学科 带头人
河南省卫生健康科技创新杰出青年人才
微信扫码关注该文公众号作者